# Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route

Source: https://onco.cc/ideas/idea-reg-non-viral-cart-manufacturing/  
OnCo record `idea-reg-non-viral-cart-manufacturing` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Putting the CAR gene into T cells without a virus removes the most expensive and delay-prone ingredient. Test whether non-viral products match viral ones.

## Summary

Transposon systems (piggyBac, Sleeping Beauty) and CRISPR-mediated targeted insertion (for example into the TRAC locus) deliver CAR constructs as DNA or RNA without lentiviral vector, cutting materials cost and removing the vector supply queue; clinical experience exists from Poseida, MD Anderson, Chinese academic groups and others, with an early piggyBac safety signal (lymphoma from integration) in one Australian programme that informs design. The proposal is a head-to-head programme establishing non-viral manufacturing as the default for new autologous and allogeneic CAR-T, with integration-site safety monitoring as a shared standard.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Non-viral CD19 CAR-T achieves transduction efficiency, persistence and 12-month response rates non-inferior to lentiviral products at a materials cost per dose lower by at least $15,000, with no excess of integration-related malignancy over five years of follow-up.
- Rationale: Vector supply is a scheduling and cost bottleneck unrelated to the biology of the product; targeted insertion may also improve product consistency by placing the CAR under endogenous regulation.
- Proposed test: Randomised phase 2 of non-viral versus lentiviral CD19 CAR-T in relapsed lymphoma with manufacturing cost, vein-to-vein time and integration-site analysis as co-primary manufacturing endpoints.
- Maturity: early-clinical
- Actor: research

## Sources

- Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018): https://doi.org/10.1001/jamaoncol.2018.0977

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- technologies: [Allogeneic (off-the-shelf) cell therapy](https://onco.cc/technologies/allogeneic-cell-therapy/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- trials: [RELIANCE](https://onco.cc/trials/reliance/), [Study of Out of Specification for Tisagenlecleucel](https://onco.cc/trials/nct04094311/), [Talicabtagene autoleucel (NexCAR19) phase 1/2](https://onco.cc/trials/talicel-phase-1-2/), [ZUMA-1](https://onco.cc/trials/zuma-1/), [ZUMA-7](https://onco.cc/trials/zuma-7/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/)
- key papers: [Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials](https://onco.cc/key-papers/paper-cd19-dlbcl-am-j-hematol-2021/), [SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies](https://onco.cc/key-papers/paper-cd19-dlbcl-clin-cancer-res-2011/), [The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19](https://onco.cc/key-papers/paper-cd19-dlbcl-cytotherapy-2020/), [Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy](https://onco.cc/key-papers/paper-hernandez-jama-oncol/)

---
JSON: https://onco.cc/api/v1/entities/idea-reg-non-viral-cart-manufacturing.json